Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

26.27USD
10:02am EDT
Change (% chg)

$-0.12 (-0.47%)
Prev Close
$26.40
Open
$26.50
Day's High
$27.00
Day's Low
$26.05
Volume
25,514
Avg. Vol
780,013
52-wk High
$33.00
52-wk Low
$16.40

Latest Key Developments (Source: Significant Developments)

Scopia Capital Management reports 12 pct passive stake in Acorda Therapeutics
Friday, 10 Mar 2017 04:59pm EST 

Scopia Capital Management LP: Scopia Capital Management LP reports 12 percent passive stake in Acorda Therapeutics Inc as of Feb 28 - SEC filing .Scopia Capital Management LP - previously reported a 9.8 percent passive stake in Acorda Therapeutics as of Dec 31, 2016.  Full Article

Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8
Friday, 10 Feb 2017 07:57am EST 

Acorda Therapeutics Inc : Acorda Therapeutics Inc - on Feb 8, 2017, Acorda Therapeutics, inc entered into settlement agreement with Apotex Corporation and Apotex Inc-sec filing . Acorda Therapeutics- as result of settlement agreement, co will be permitted to market generic version of ampyra in united states at specified date in 2025 . Acorda Therapeutics Inc - settlement to resolve pending patent litigation brought by company against Apotex involving ampyra extended-release tablets . Acorda Therapeutics - parties will request court enter consent order, in which it will dismiss company's litigation against apotex referred to above .Acorda Therapeutics Inc - details of settlement are confidential.  Full Article

Acorda announces 2016 AMPYRA net sales and 2017 financial guidance
Monday, 9 Jan 2017 06:00am EST 

Acorda Therapeutics Inc : Acorda announces 2016 AMPYRA net sales and 2017 financial guidance at J.P. Morgan healthcare conference . Sees FY 2017 sales $535 million to $545 million . Q4 sales $132 million versus I/B/E/S view $137.5 million . Acorda Therapeutics - continue to enroll Phase 3 study of tozadenant in people with parkinson's and expect topline data from study in Q1 of 2018 . Acorda Therapeutics Inc - at year-end 2016, company projects cash, cash equivalents and investments of approximately $155 million (unaudited) .Acorda Therapeutics - on track to announce topline data from CVT-301 phase 3 efficacy,long-term safety trials for treatment of off periods in parkinson's.  Full Article

Acorda Therapeutics Q3 non-GAAP loss per share $0.04
Thursday, 27 Oct 2016 06:00am EDT 

Acorda Therapeutics Inc : Acorda provides financial and pipeline update for third quarter 2016 . Q3 non-GAAP loss per share $0.04 . Q3 GAAP loss per share $0.28 . Q3 revenue $128.8 million versus I/B/E/S view $134 million . Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S .Acorda Therapeutics inc - company is reiterating 2016 Ampyra net sales guidance of $475-$485 million.  Full Article

Arbitral Tribunal confirms Acorda's redemption right regarding Biotie shares
Monday, 26 Sep 2016 02:30am EDT 

Biotie Therapies Oyj : Arbitral Tribunal confirmed Acorda's redemption right regarding Biotie shares .Biotie shares trading has been terminated.  Full Article

Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filing
Thursday, 2 Jun 2016 07:53am EDT 

Acorda Therapeutics Inc : On June 1, co, units entered into a credit agreement - SEC filing . Initial availability under facility is approximately $58 million. .Agreement provides company with a three-year senior secured revolving credit facility in maximum amount of $60 million.  Full Article

Biotie Therapies announces final results of subsequent offer period of Acorda Therapeutics tender offer
Monday, 2 May 2016 09:40am EDT 

Biotie Therapies Oyj:Final results of the subsequent offer period of Acorda Therapeutics tender offer for all securities in Biotie.38.4 million shares and 58,121 American Depositary Shares (ADSs) were tendered during subsequent offer period.Together with other equity interests tendered in tender offer during initial offer period, about 97.36 percent of all shares and votes were tendered.  Full Article

Acorda Therapeutics Inc announces results from mid-phase clinical trial of CVT-301
Wednesday, 20 Apr 2016 07:00am EDT 

Acorda Therapeutics Inc:Acorda Announces Results From Phase 2b Clinical Trial Of CVT 301 for treatment of off periods in parkinson's disease published in movement disorders.Participants receiving CVT-301 showed a statistically significant and clinically important reduction in average updrs III score.No serious adverse events reported in drug group, incidence of drug-related adverse events was similar between treatment groups.No adverse events related to cardiovascular or lung function reported.  Full Article

Acorda Therapeutics announces preliminary tender offer results for Biotie Therapies
Monday, 11 Apr 2016 08:55am EDT 

Acorda Therapeutics Inc:Acorda Therapeutics ("Acorda") announces preliminary tender offer results and acceptance of shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie Therapies Corp tendered in tender offer.Shares and ADSs tendered in the Tender Offer represent about 92.37 pct of all shares and votes in Biotie (excluding treasury shares held by Biotie).  Full Article

Acorda Therapeutics Inc gives FY 2016 AMPYRA net sales guidance
Monday, 11 Jan 2016 07:30am EST 

Acorda Therapeutics Inc:Expects AMPYRA FY 2016 net sales guidance of $475 mln - $485 mln.  Full Article

More From Around the Web

Hedge fund manager Kyle Bass loses challenge to Acorda patents

By Jan Wolfe The U.S. Patent and Trademark Office on Thursday rejected hedge fund manager Kyle Bass' challenge to four patents on Acorda Therapeutics' flagship multiple sclerosis drug Ampyra.